Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Merck
Johnson and Johnson
Dow
Mallinckrodt

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR BUMETANIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Bumetanide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00372762 ↗ Bumetanide Versus Furosemide in Heart Failure Withdrawn University of Western Ontario, Canada Phase 3 2011-01-01 Patients with NYHA FC II-III heart failure will be randomized in a cross-over fashion to 8 weeks of bumetanide versus furosemide therapy (equipotent dose), to test whether bumetanide therapy has a superior effect on insulin resistance compared to furosemide. Patients will be subject to a frequently sampled intravenous glucose tolerance test (FSIGT) with minimal model (MINMOD) analysis to assess insulin resistance and to a 6-minute walk test (6MWT) to assess functional capacity; patient recruitment and retention success, as well as medication adherence, will also be assessed.
NCT00372762 ↗ Bumetanide Versus Furosemide in Heart Failure Withdrawn Lawson Health Research Institute Phase 3 2011-01-01 Patients with NYHA FC II-III heart failure will be randomized in a cross-over fashion to 8 weeks of bumetanide versus furosemide therapy (equipotent dose), to test whether bumetanide therapy has a superior effect on insulin resistance compared to furosemide. Patients will be subject to a frequently sampled intravenous glucose tolerance test (FSIGT) with minimal model (MINMOD) analysis to assess insulin resistance and to a 6-minute walk test (6MWT) to assess functional capacity; patient recruitment and retention success, as well as medication adherence, will also be assessed.
NCT00830531 ↗ Pilot Study of Bumetanide for Newborn Seizures Completed Charles H. Hood Foundation Phase 1 2010-01-01 The main goal of the study is to obtain pharmacokinetic and safety data of bumetanide in newborns with refractory seizures. The overall hypothesis is that bumetanide, added to conventional antiepileptic (antiseizure) medications, will be a safe and well tolerated medication, compared with conventional antiepileptic drugs alone.
NCT00830531 ↗ Pilot Study of Bumetanide for Newborn Seizures Completed Citizens United for Research in Epilepsy Phase 1 2010-01-01 The main goal of the study is to obtain pharmacokinetic and safety data of bumetanide in newborns with refractory seizures. The overall hypothesis is that bumetanide, added to conventional antiepileptic (antiseizure) medications, will be a safe and well tolerated medication, compared with conventional antiepileptic drugs alone.
NCT00830531 ↗ Pilot Study of Bumetanide for Newborn Seizures Completed Harvard Catalyst- Harvard Clinical and Translational Science Center Phase 1 2010-01-01 The main goal of the study is to obtain pharmacokinetic and safety data of bumetanide in newborns with refractory seizures. The overall hypothesis is that bumetanide, added to conventional antiepileptic (antiseizure) medications, will be a safe and well tolerated medication, compared with conventional antiepileptic drugs alone.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Bumetanide

Condition Name

Condition Name for Bumetanide
Intervention Trials
Heart Failure 4
Acute Decompensated Heart Failure 3
Autism Spectrum Disorder (ASD) 2
Congestive Heart Failure 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Bumetanide
Intervention Trials
Heart Failure 11
Autistic Disorder 5
Renal Insufficiency, Chronic 3
Child Development Disorders, Pervasive 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Bumetanide

Trials by Country

Trials by Country for Bumetanide
Location Trials
France 20
United States 11
Italy 10
Poland 8
Spain 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Bumetanide
Location Trials
Texas 2
New York 2
North Carolina 1
Ohio 1
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Bumetanide

Clinical Trial Phase

Clinical Trial Phase for Bumetanide
Clinical Trial Phase Trials
Phase 4 4
Phase 3 6
Phase 2 6
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Bumetanide
Clinical Trial Phase Trials
Completed 9
Recruiting 3
Active, not recruiting 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Bumetanide

Sponsor Name

Sponsor Name for Bumetanide
Sponsor Trials
ADIR, a Servier Group company 2
Institut de Recherches Internationales Servier 2
Ministry of Health, France 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Bumetanide
Sponsor Trials
Other 42
Industry 11
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Boehringer Ingelheim
Medtronic
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.